Maegim한국어

동구바이오제약

006620KOSDAQSector: Pharma & Biotech
₩3,540▲ 1.00%Market cap ₩100.8BAs of Jul 21, 2026 close · updated once daily
B
Grade B60.8 ptsTop 32% of 2,523 stocks
Financial strength
51.1
Growth momentum
36.0
Price attractiveness
89.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

51.1
How much debt does it carry relative to equity?
Debt-to-equity ratio
121.1%
✗ Below median · Top 83.1% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
91.9%
✗ Below median · Top 79.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
3.8%
✓ Above median · Top 32.3% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
33.1%
✓ Above median · Top 1% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

36.0
How much did revenue grow in a year?
Revenue growth (YoY)
-2.6%
✗ Below median · Top 71.9% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
7.6%
✓ Above median · Top 41.5% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-27.1%
✗ Below median · Top 75.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-45.7%
✗ Below median · Top 67.5% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

89.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
2.0x
✓ Above median · Top 0.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.66x
✓ Above median · Top 20.5% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15